Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.46 |
| ▸ | HTR3A | P46098 | 5/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.42 |
| ▸ | HTR3B | O95264 | 3/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16366822 | 0.85 | PDE10A (0.51) | HRH4PDE10A | |
| SCHEMBL11919280 | 0.81 | HTR2C (0.60) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL15582906 | 0.81 | KMT2A (0.42) | PDE10A | |
| SCHEMBL2640550 | 0.80 | HRH4 (0.54) | HRH4HTR3AHRH3 | |
| SCHEMBL2401439 | 0.78 | HTR3A (0.58) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL14618026 | 0.77 | HTR3A (0.62) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL12988898 | 0.77 | HRH4 (0.37) | HRH4HRH3PDE10A | |
| SCHEMBL17525869 | 0.76 | HTR3A (0.59) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL419964 | 0.76 | HTR3A (0.47) | HRH4HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL3056725 | 0.76 | KDM4E (0.64) | HRH4HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | HRH4 2544/4885HTR3A 1933/4885HTR3E 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.